Bausch + Lomb (BLCO) Competitors $14.72 -0.18 (-1.18%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. ZBH, SNN, SOLV, PEN, STVN, IRTC, GKOS, TMDX, SLNO, and NVSTShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), and Envista (NVST). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Its Competitors Zimmer Biomet Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Glaukos TransMedics Group Soleno Therapeutics Envista Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation. Is ZBH or BLCO more profitable? Zimmer Biomet has a net margin of 10.51% compared to Bausch + Lomb's net margin of -5.58%. Zimmer Biomet's return on equity of 12.76% beat Bausch + Lomb's return on equity.Company Net Margins Return on Equity Return on Assets Zimmer Biomet10.51% 12.76% 7.21% Bausch + Lomb -5.58%2.33%1.12% Do analysts prefer ZBH or BLCO? Zimmer Biomet presently has a consensus price target of $112.44, indicating a potential upside of 13.16%. Bausch + Lomb has a consensus price target of $15.60, indicating a potential upside of 5.84%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, equities research analysts clearly believe Zimmer Biomet is more favorable than Bausch + Lomb.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 2 Sell rating(s) 8 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.48Bausch + Lomb 2 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.08 Which has more volatility and risk, ZBH or BLCO? Zimmer Biomet has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Does the media favor ZBH or BLCO? In the previous week, Zimmer Biomet had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 10 mentions for Zimmer Biomet and 7 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.10 beat Bausch + Lomb's score of 0.54 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in ZBH or BLCO? 88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 0.7% of Zimmer Biomet shares are held by company insiders. Comparatively, 0.2% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, ZBH or BLCO? Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimmer Biomet$7.68B2.56$903.70M$4.1124.18Bausch + Lomb$4.79B1.09-$317M-$0.78-18.90 SummaryZimmer Biomet beats Bausch + Lomb on 17 of the 17 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$5.22B$8.15B$6.11B$21.99BDividend YieldN/A2.81%5.51%3.56%P/E Ratio-18.9173.4785.6429.82Price / Sales1.0940.21586.65102.30Price / Cash8.1223.0126.3018.33Price / Book0.796.8713.204.63Net Income-$317M$247.60M$3.30B$1.01B7 Day Performance-2.26%2.58%5.17%0.53%1 Month Performance-1.70%2.61%8.88%2.73%1 Year Performance-21.48%11.89%88.05%14.35% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb1.8799 of 5 stars$14.72-1.2%$15.60+6.0%-21.7%$5.21B$4.79B-18.8513,500Analyst ForecastZBHZimmer Biomet4.7305 of 5 stars$98.13-0.1%$113.16+15.3%-5.5%$19.46B$7.68B23.8817,000Positive NewsSNNSmith & Nephew SNATS3.4557 of 5 stars$35.48+0.2%$36.00+1.5%+19.8%$15.42B$5.81B16.4217,349SOLVSolventum2.7351 of 5 stars$72.09+1.0%$85.44+18.5%+9.1%$12.37B$8.25B33.3822,000PENPenumbra4.6762 of 5 stars$252.02-0.5%$302.93+20.2%+31.1%$9.88B$1.19B67.034,500STVNStevanato GroupN/A€25.46-0.8%N/A+29.5%€7.71B€1.19B47.155,521IRTCiRhythm Technologies1.149 of 5 stars$169.50-0.8%$167.50-1.2%+180.2%$5.49B$591.84M-57.852,000GKOSGlaukos4.5087 of 5 stars$81.24+1.7%$123.58+52.1%-33.9%$4.58B$383.48M-49.24780TMDXTransMedics Group3.1373 of 5 stars$112.64-1.1%$125.40+11.3%-18.0%$3.88B$441.54M58.36210Positive NewsSLNOSoleno Therapeutics4.1779 of 5 stars$68.16+4.9%$115.09+68.9%+17.8%$3.45BN/A-16.4630Analyst ForecastNVSTEnvista3.7019 of 5 stars$20.22-0.7%$20.92+3.5%+9.6%$3.38B$2.51B63.1712,300 Related Companies and Tools Related Companies Zimmer Biomet Competitors Smith & Nephew SNATS Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors iRhythm Technologies Competitors Glaukos Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Envista Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
